Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13894270 | 0.92 | PTGER1 (0.61) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL13894121 | 0.91 | PTGER1 (0.60) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL12487799 | 0.90 | PTGER1 (0.65) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL12481864 | 0.90 | PTGER1 (0.59) | PTGER1TP53 | |
| SCHEMBL13894369 | 0.88 | PTGER1 (0.57) | PTGER1SMN1; SMN2 | |
| SCHEMBL13894271 | 0.88 | PTGER1 (0.65) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL13894184 | 0.88 | PTGER1 (0.65) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL12487610 | 0.87 | PTGER1 (0.59) | PTGER1CNR2MEN1KMT2AMAPT | |
| SCHEMBL13894483 | 0.85 | PTGER1 (0.66) | PTGER1SMN1; SMN2 | |
| SCHEMBL13894352 | 0.85 | PTGER1 (0.62) | PTGER1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | PTGER1 1/4885CNR2 6/4885MEN1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.